
Quarterly ResultMay 14, 2026, 04:38 PM
Fortress Biotech Q1 Net Income $110.4M on PRV Sale; Cash $255.8M
AI Summary
Fortress Biotech reported a net income of $110.4 million for Q1 2026, a significant improvement from a loss of $10.6 million in Q1 2025, primarily driven by a $158.9 million gain from the sale of a Rare Pediatric Disease priority review voucher. The company's cash and cash equivalents surged to $255.8 million. Despite an operating loss of $7.7 million, product revenue increased by 21.2% year-over-year, and R&D expenses decreased substantially.
Key Highlights
- Gain on sale of priority review voucher: $158.9 million.
- Net income attributable to Fortress: $110.4 million, up from $(10.6) million YoY.
- Basic EPS: $3.44, up from $(0.48) in Q1 2025.
- Cash and cash equivalents: $255.8 million as of March 31, 2026, up from $79.4 million.
- Product revenue, net: $15.9 million, a 21.2% increase YoY.
- Loss from operations: $(7.7) million, improved from $(22.3) million YoY.
- Research and development expenses: $0.5 million, down from $3.9 million YoY.
- Total assets: $356.9 million as of March 31, 2026.
Price Impact
More from FBIO